Placebo Group
Dietary SupplementSubjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
NCT Number: NCT02604641
Objective of the study is to determine the influence of dietary supplementation with coenzyme Q10 (CoQ10) on skin conditions. 33 healthy female subjects will be randomly assigned to a placebo group, a low-dose (LD) group receiving 50 mg CoQ10/day and a high-dose group (HD) receiving 150 mg CoQ10/day (11 subjects per group). A water-soluble form of CoQ10 with improved bioavailability (Quvital syrup with Q10vital®, Valens Int. d.o.o., Slovenia) will be used. Various skin parameters will be evaluated before the supplementation (the baseline), after 6 and after 12 weeks of supplementation. To evaluate the photoprotective potential of CoQ10 the minimal erythema dose (MED) will be determined before (the baseline) and after 12 weeks of the supplementation.
Looking for future studies?
Notify Me45 year–60 year
Female
Interventional
Not applicable
Objective of the study is to determine the influence of dietary supplementation of CoQ10 in form of water-soluble Q10vital® on skin conditions. 33 healthy female subjects will be randomly assigned to a placebo group, a low-dose (LD) group receiving 50 mg CoQ10/day and a high-dose group (HD) receiving 150 mg CoQ10/day (11 subjects per group). A water-soluble form of CoQ10 with improved bioavailability (Quvital syrup with Q10vital®, Valens Int. d.o.o., Slovenia) will be used. The placebo or CoQ10 will be administered in the form of a syrup; all subjects will consume 5 mL of syrup daily for 12 weeks. The photoprotective potential of CoQ10 will be evaluated with a determination of the minimal erythema dose (MED) before (the baseline) and after 12 weeks of the supplementation. Other skin parameters will be evaluated before supplementation (the baseline), after 6 and after 12 weeks of supplementation. Comparison will be done as the mean of the individual ratios. The differences between the before-after condition will be analyzed with the statistical test of analysis of variance. In case of failure to find homogeneity in the variances the nonparametric ANOVA, the Willcoxon test, will be used. The results will be expressed as mean ± standard error for each group with a significance level of 0.05 for all the statistical tests.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
Time frame: after 12 weeks of the supplementation
Minimal erythema dose (MED) of the skin will be determined. Skin on gluteal part of the body will be exposed to 10 different doses of UVB light and 24 hours after exposure MED will be determined.Higher MED indicates better photoprotective function of the skin.
Time frame: after 6 and after 12 weeks of the supplementation
Area of selected periorbital wrinkles will be quantitatively assessed using CSI programme.
Time frame: after 6 and after 12 weeks of the supplementation
Volume of selected periorbital wrinkles will be quantitatively assessed using CSI programme.
Time frame: after 6 and after 12 weeks of the supplementation
Expert assessment of wrinkles at different face areas (periorbital, frontal, glabelar, nasolabial areas etc.) will be done according to Lemperle Wrinkle assessment scale.
Time frame: after 6 and after 12 weeks of the supplementation
Ultrasound (US) images of the dermis will be taken and intensity of the dermis determined. Higher intensity of the dermis US images indicates improvement of the collagen and elastin network.
Time frame: after 6 and 12 weeks of the supplementation
Dermis thickness will be measured with ultrasound imaging of the skin.
VIST - Faculty of Applied Sciences
Other
Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin: Randomised, Double-blind, Placebo-controlled Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02603029
Ageing, PHOTOPROTECTION
View Trial DetailsNCT01529983
Wrinkles
Chicago, Illinois, United States
View Trial DetailsNCT06724510
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases
Beijing, China
View Trial DetailsNCT06657365
Anti-Aging, Facial Wrinkles
Beijing, China
View Trial Details